View Older Stories View More Recent Stories

Jan 27, 2022 07:30AM Biogen (BIIB) Provides Update on Phase 4 ENVISION Confirmatory Study of ADUHELM
Jan 27, 2022 07:30AM Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Jan 27, 2022 07:30AM Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Jan 4, 2022 07:34AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Jan 4, 2022 07:34AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Jan 4, 2022 07:31AM Biogen (BIIB) Exercises Option with Ionis (IONS) to Develop and Commercialize Investigational ASO for SMA
Jan 4, 2022 07:30AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Dec 23, 2021 06:30PM INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION
Dec 22, 2021 07:32AM Biogen (BIIB) and Eisai Announce Japanese Agency Seeks Additional Data; Aducanumab Remains under Review
Dec 22, 2021 07:30AM Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
Dec 22, 2021 07:30AM Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
Dec 20, 2021 07:02AM Biogen (BIIB) Reduces Price for ADUHELM to Improve Access for Patients with Early Alzheimer’s Disease
Dec 20, 2021 07:00AM Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
Dec 20, 2021 07:00AM Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
Dec 17, 2021 06:45AM Biogen's (BIIB) Aduhelm Receives Negative Opinion on Marketing Authorization Application in the EU
Dec 17, 2021 06:43AM Update on Regulatory Submission for Aducanumab in the European Union
Dec 17, 2021 06:43AM Update on Regulatory Submission for Aducanumab in the European Union
Dec 16, 2021 07:03AM Biogen (BIIB) and Eisai Issue Update on the Phase 4 Confirmatory Study of ADUHELM
Dec 16, 2021 07:00AM Update on the Phase 4 Confirmatory Study of ADUHELM®
Dec 16, 2021 07:00AM Update on the Phase 4 Confirmatory Study of ADUHELM®
Dec 14, 2021 07:03AM Biogen (BIIB) Announces New Collaboration with TheraPanacea to Advance Digital Health for Personalized Medicine in Neuroscience
Dec 14, 2021 07:03AM Biogen (BIIB) and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Dec 14, 2021 07:00AM Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Dec 14, 2021 07:00AM Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Dec 8, 2021 06:31AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce New Analyses from LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at ACNP Congress
Dec 8, 2021 06:30AM Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
Dec 1, 2021 06:31AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Dec 1, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Nov 17, 2021 07:48AM Biogen (BIIB) Receives Negative Trend Vote on Regulatory Review of Aducanumab in the EU
Nov 17, 2021 07:30AM Update on Regulatory Review of Aducanumab in the European Union
Nov 17, 2021 07:30AM Update on Regulatory Review of Aducanumab in the European Union
Nov 16, 2021 09:20AM Biogen (BIIB) Granted Marketing Authorization for VUMERITY by the European Commission
Nov 16, 2021 09:20AM The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis
Nov 16, 2021 09:20AM The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis
Nov 16, 2021 05:48AM Biogen (BIIB) Announces Alfred W. Sandrock, Head of Research & Development Will Retire
Nov 15, 2021 07:44PM Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
Nov 15, 2021 07:44PM Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
Nov 15, 2021 07:30AM Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
Nov 15, 2021 07:30AM Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
Nov 11, 2021 05:15PM New Phase 3 Data Show Positive Correlation of Biogen (BIIB) ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease
Nov 11, 2021 05:10PM New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
Nov 11, 2021 05:10PM New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
Nov 11, 2021 12:00PM Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Confer
Nov 11, 2021 11:20AM Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference
Nov 10, 2021 02:57PM Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD
Nov 3, 2021 07:30AM Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Nov 3, 2021 07:30AM Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Oct 19, 2021 06:33AM SAGE Therapeutics (SAGE), Biogen (BIIB) to Submit NDA for Zuranolone to FDA in Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
Oct 19, 2021 06:30AM Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Oct 18, 2021 05:26AM Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS
View More Recent Stories View Older Stories